Sep. 11 at 8:44 PM
$CRVO btw abstracts out https://isftd2026.org/program/ nitial Biomarker Results from A Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia
#4007
Irwin, DJ1; Boeve, BF2; Grant, IM3; Gardner, A4; Blackburn, K5; Alam, JJ6
1 - Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania
2 - Department of Neurology, Mayo Clinic
3 - Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Northwestern Feinberg School of Medicine
4 - CervoMed Inc.
5 - CervoMed Inc
6 - CervoMed. Inc
Introduction:
p38α plays a key role in pathogenic tau phosphorylation and aggregation, and p38α inhibition reduces tau pathology in preclinical models. In P301S tau-transgenic mice, neuronal p38α deficiency reduces tau pathology and improves behavioral outcomes. Similarly, the p38α kinase inhibitor neflamapimod reduced pathogenic tau phosphorylation in IPS-derived neurons from
